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Case presentation
A 40-year-old male was admitted to the University Hospital of
Nijmegen because of rapidly progressive renal insufficiency. Two
weeks before admission, he had been given penicillin injections because
of a sore throat and fever. Three days later he developed macroscopic
hematuria, arthralgias, and hemoptysis. On admission, his blood pres-
sure was normal. There was no presacral or peripheral edema. Physical
examination of the heart and lungs revealed no abnormalities . There
was no skin rash. The remainder of his general examination was
unremarkable. Urinalysis revealed 1 + protein, no glucose, many red
blood cells, and occasional red blood cell casts. Urine output was 400
ml in the first 24 hours. The serum creatinine was 1 1 . 1 mg/dl; endoge-
nous creatinine clearance, 1 .5 mI/mm; BUN, 88 mg/dl; and 24-hour
protein excretion, 1 .0 g. The serum C3 was normal. Anti-GBM anti-
bodies were not present in the serum. Antibodies against neutrophil
cytoplasm (ANCA) were not measured. The chest x-ray disclosed
bilateral pulmonary infiltrates. A percutaneous renal biopsy disclosed
diffuse, necrotizing, extracapillary glomerulonephritis with granular
staining of 1gM and C3 along the glomerular capillary wall. Small
vessels were normal; larger vessels were not present in the biopsy
specimen. A diagnosis of systemic necrotizing vasculitis was made, and
the patient was given prednisone, 60 mg, and cyclophosphamide, 150
mg, daily. Hemodialysis was started, but subsequently his renal func-
tion improved, and the pulmonary lesions disappeared; one month after
admission, hemodialysis was discontinued. On discharge, creatinine
clearance was 19 ml/min. Despite continuous treatment with cyclophos-
phamide (100 mg/day) and low-dose prednisone (10 mg/day), his renal
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function gradually deteriorated. After one year, hemodialysis again was
necessary.
At age 42, after 12 months of hemodialysis, the patient received a
cadaveric renal allograft. The crossmatch was negative and there was
one HL-A incompatibility at the B locus; HL-A—DR typing was not
carried out. The right donor kidney had two arteries that were anasto-
mosed separately to the left external iliac artery. Conventional immu-
nosuppressive treatment (azathioprine, 150 mg/day) and prednisone
(initial dose, 200 mg/day; maintenance dose, 15 mg/day) was employed.
The allograft functioned immediately. The patient was discharged on
the 26th postoperative day. At that time, blood pressure was 140/80 mm
Hg, creatinine clearance was 73 ml/min, and an intravenous urogram
showed no abnormalities.
After 2 months, the patient developed hypertension (170/110 mm Hg)
and proteinuria of 1—2 g/liter. Allograft rejection was diagnosed after 6
months on the basis of increased proteinuria and a gradual rise of the
serum creatinine. Treatment with a short course of high-dose oral
prednisone did not improve renal function. Renal biopsy, performed
one year after transplantation, revealed chronic vascular rejection.
Because the hypertension was severe and responded only partially to
treatment with propranolol, minoxidil, and furosemide, renal arteriog-
raphy was performed 17 months after transplantation (Fig. 1). The
arteriogram disclosed 90% stenosis (with poststenotic dilation) of the
origin of the artery supplying the lower pole of the graft. Appearance of
the contrast medium was delayed in the lower pole. The upper artery,
which supplied the major part ofthe kidney, was slightly narrowed at its
origin, but filling of its branches was not delayed. Because the contri-
bution of the lower renal artery stenosis to the severe hypertension was
not clear, and because the biopsy showed severe vascular rejection,
reconstruction of the stenosis was not attempted. Renal function
gradually deteriorated further. Six months later, almost 2 years after
transplantation, hemodialysis was resumed and the allograft was re-
moved.
The grafted kidney weighed 110 g; a surprising difference existed
between the lower pole (supplied by the stenotic artery), which had a
depressed, smooth, and brown-red surface, and the remaining four-
fifths of the kidney, which had a pale, swollen aspect and a fine nodular
surface (Fig. 2). On longitudinal section the lower pole appeared to be
atrophic. Here the cortex was narrow and sharply demarcated from the
medulla. The remainder of the graft had a cortex of normal width with
a brownish-yellow color and a poor demarcation from the medulla.
Histologic examination revealed chronic vascular rejection in the upper
part of the kidney, findings consistent with those in the previous renal
biopsy. Focal and segmental proliferation of mesangial cells was
present in the glomeruli, as were thickening and splitting of the
basement membrane. The glomerular capillaries showed focal adhe-
sions to Bowman's capsule, and a few epithelial crescents were visible
(Fig. 3A). The tubules were atrophic and interstitial fibrosis was
present. The arterial vessels showed extensive intimal fibrosis. Immu-
nofluorescent microscopy revealed glomerular deposits of 1gM, C lq,
C4, and C3, predominantly in the capillary walls (Fig. 3B). By contrast,
the lower pole (supplied by the stenotic artery) showed only signs of
chronic ischemia. The otherwise-normal glomerular capillaries were
slightly collapsed and the tubules were markedly atrophic; the glomeruli
thus appeared crowded (Fig. 3C). No immunoglobulin deposits were
found in the glomeruli or in the vessels (Fig. 3D).
After removal of the transplanted kidney, cytotoxic antibodies of
broad specificity, predominantly directed against B lymphocytes, were
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Fig. 1. Angiogram of renal allograft. The two renal arteries (arrows)
have been anastomosed separately to the left external iliac artery.
Contrast medium already has reached the upper part of the kidney via
the normal upper artery. The lower artery shows a severe stenosis at its
origin with a poststenotic dilation and delayed appearance of contrast
medium.
demonstrable in the serum during a period of 3 months. Thereafter,
these antibodies disappeared. Four months after transplantectomy, he
received a second transplant. After seven months this second kidney
was lost as a consequence of a vascular rejection.
Discussion
PROF. ROBERT A. P. KOENE (Professor of Nephrology,
Nijmegen University School of Medicine; Head, Division of
Nephrology, University Hospital, Nijmegen, The Netherlands):
This patient is unusual in that he had two renal arteries in his
transplant kidney; significant stenosis developed in the lower
artery, and the "protected" and "unprotected" parts of the
transplanted kidney responded differently from each other. The
post-stenotic segment of the transplanted kidney in this patient
apparently was protected against immune attack by the host.
The ongoing rejection process that caused loss of the graft
probably was governed by destructive antibodies. In fact,
lymphocytotoxic antibodies were demonstrable in the circula-
tion of the patient during the first weeks after the transplanted
kidney was removed. In the normally perfused upper segment
of the graft, pathologic examination revealed a typical picture of
Fig. 2. Macroscopic appearance of kidney graft after removal. The
upper part of the kidney is pale and swollen. The lower pole is atrophic.
so-called transplant glomerulopathy with extensive deposition
of immunoglobulins and complement components in the capil-
lary walls. The critical observation, the apparent protection of
the lower pole, has many features in common with a phenom-
enon that has been observed in experimental transplantation of
organs and tissues, that is, the occurrence of "graft adapta-
tion. ' ' This phenomenon will be the central focus of my
discussion. The findings in this patient resemble reports on a
few patients with unilateral glomerulonephritis in whom the
unaffected kidney showed signs of decreased blood flow as a
consequence of renal artery stenosis or long-standing hydrone-
phrosis. I will discuss these experimental and clinical observa-
tions, delineating the factors that csused the exceptional form
of partial graft protection in this patient.
Factors in long-term graft acceptance
How can we best assure our patients of the long-term success
of renal transplantation? The ideal method of obtaining long-
term graft survival is complete matching of donor and recipient
histocompatibility antigens. In clinical transplantation, unfortu-
nately, this can be achieved only in identical twins. Neverthe-
less, long-term graft survival can be achieved in histoincompat-
ible combinations, and it is well known that with increasing time
after transplantation, the risk of rejection diminishes. Table 1
.4
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Fig. 3. Histology of removed graft. A glomerulus in the upper part of the kidney shows "transplant glomerulopathy" (A) with deposits of 1gM
predominantly along the capillary wall (B). A glomerulus in the lower, poststenotic segment shows only signs of ischemia (C). In this part 1gM is
present in tubular casts, but not in the glomerular capillaries (D).
lists factors that play a role in long-term graft survival. In the
host, nonspecific suppression of the immune reaction by corti-
costeroids, antimitotic drugs, or cyclosporine is important.
Other, more specific, protective mechanisms also might be
operative, such as deletion of antigen-reactive cells (the defini-
tion of tolerance), preferential proliferation of suppressor T-
cells, or the production of specific, blocking (so-called enhanc-
ing) or antiidiotypic antibodies. Although the existence of these
specific protective mechanisms can be demonstrated in selected
animal models, the evidence for their presence in human
transplantation is weak. Lymphocytes of patients with long-
established, well-functioning kidney grafts no longer generate
an in-vitro, cytotoxic response to donor cells. Their response to
cells from individuals of different HL-A type remains normal
[1]. Whether specific unresponsiveness is due to the generation
of suppressor T-cells or to elimination of antigen-reactive
clones is not known. Some hemodialysis patients do develop
blocking antibodies after multiple blood transfusions; these
antibodies are directed against the receptors of the T-cells
specifically involved in the recognition of a particular HL-A
antigen (antiidiotypic antibodies). Kidneys of the right HL-A
specificity subsequently transplanted into these patients survive
for prolonged periods [21. These interesting data, however, do
not help to clarify the striking observations in the case pre-
if
Nonspecific immunosuppression
Deletion of antigen-reactive cells (tolerance)
Suppressor T-cells
Antibodies (enhancing or antiidiotypic)
Graft
Loss of passenger cells
Adaptation
sented, because changes in the graft and not in the host
probably were responsible for the protection of the lower part
of the graft.
Where do graft factors influence the outcome of transplanta-
tion? Changes in the graft per se can affect the immune response
at two distinct levels (Fig. 4). At the afferent level, the concept
of the so-called passenger cell has received much attention. In
addition to resident cells, most organs and tissues harbor
circulating and semisessile cells derived from the bone-marrow,
such as lymphocytes, monocytes, macrophages, and dendritic
cells. During the first weeks after transplantation, these cells
gradually disappear from the graft and are replaced by host
cells, hence their name "passenger cells." These passenger
Table I. Factors contributing to long-term graft survival
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Fig. 4. Schematic representation of the
allograft reaction. Foreign antigens (either in
soluble form or on the surface of passenger
cells) are released from the graft and
recognized in the draining lymph nodes
(afferent limb). This leads to the formation of
sensitized lymphocytes and antibodies that
attack the graft (efferent limb). (From Ref. 3.)
cells, especially the dendritic cells and monocyte-macrophages,
play an important role in antigen presentation and thus in the
triggering of the immune response. Their role has been demon-
strated most convincingly in experimental transplantation of
thryoid and pancreatic tissue. Passenger cells can be removed
from these tissues by a short period of culture prior to trans-
plantation; subsequent grafting leads to prolonged and often
lifelong survival [4, 5]. The observation that the grafts were
promptly rejected when the recipients were challenged with
donor lymphoid cells [6, 71 demonstrated that the prolonged
survival indeed was caused by a loss of the passenger cells, and
not by a loss of antigenicity during culture. This mechanism
could be important for transplantation in the future, especially
for pancreatic transplantation. I will not discuss it further here,
however, because it concerns a decrease in immunogenicity of
a tissue to be transplanted into a host who has not encountered
the foreign graft antigens earlier. In contrast, the phenomenon
of protection of part of the kidney observed in today's patient
occurred in the presence of an ongoing immune response.
Definition of graft adaptation
The first description of graft adaptation Stems from the work
of the Woodruffs carried out almost 40 years ago [8]. They
grafted allogeneic thyroid tissue to the anterior chambers of the
eyes of guinea pigs. The grafts became vascularized from the
host iris yet showed permanent survival in most of the recipi-
ents. If thyroid tissue from the same donor was grafted subcu-
taneously simultaneously with the eye grafts, both thyroid
grafts were rejected. If subcutaneous grafts were placed 5 to 6
weeks after the anterior chamber transplants, however, the
established grafts in the eye underwent no changes, but the
subcutaneous grafts were rejected. From these observations
Woodruff hypothesized that ". . . homo-transplants become
less vulnerable as time goes on, and, after a certain critical
period, are capable of surviving in the face of a high degree of
immunity in the recipient, which they would not have been able
to withstand earlier in their life history" [9]. In later studies
Woodruff observed a similar phenomenon in skin grafts in rats.
Second skin grafts applied to recipients already carrying a
well-established skin graft from the same donor sometimes
were rejected while the first graft remained viable [101. Wood-
ruff coined the term "adaptation" in his first study, and this
term has been Used by subsequent investigators for this puz-
zling phenomenon. Some authors have used "adaptation" to
designate decreased immunogenicity of the graft by the removal
of passenger cells, but this phenomenon utilizes a completely
different mechanism of graft protection, so I prefer to use to the
classic definition coined by Woodruff. I use the term "adap-
tation" only for situations in which the graft is protected against
an intact or ongoing immune response.
Now I will explore the different aspects of adaptation against
cell-mediated and antibody-mediated rejection and then turn to
the mechanism of adaptation. I will close with a discussion of
the important role of hemodynamic factors.
Adaptation to cell-mediated rejection
In the few studies of the phenomenon of adaptation that
followed the original observations by Woodruff, murine skin
grafts have been used as the primary model. When allogeneic
skin is grafted onto untreated mice, it usually is rejected
between 10 and 15 days after transplantation. Graft survival can
be prolonged by immunosuppressive treatment, however. By
treating the recipient mice with antilymphocyte serum during
the first 5 days after transplantation, Nirmul et al prolonged
graft survival to 30 days [11]. When a second graft from the
same donor was placed 14 days after the first graft, this second
graft was rejected after 10 to 12 days, when the first graft
showed no signs of rejection. We obtained comparable results
using a different immunosuppressive regimen consisting of
specific, blocking (so-called enhancing) antibodies, combined
with whole-body irradiation on the day prior to grafting [121.
Mice carrying a skin allograft received a second graft of the
same donor strain after 13 days. The pattern of rejection of the
first and second grafts is shown in Figure 5. We found a
significant 2- to 4-day difference in survival between the two
grafts. The first grafts showed no visual evidence of destruction
when the second grafts were totally destroyed; the first grafts
thus met the criterion for graft adaptation. Histologic studies of
skin grafts in these models have shown that the rejection
process is cell mediated. The findings I have described there-
fore prove that adaptation to cellular rejection occurs. The
adaptation is not caused by a decreased immune responsiveness
Sensitized
lymphocyte
LympnyT
Antibody antibody
mediated
response
Antigen
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Fig. 5. Adaptation to cell-mediated rejection. Allogeneic skin was
grafted onto immunosuppressed mice. The first grafts survived for 27.7
+ 2.0 days, whereas second grafts from the same donor strain, placed
on day 13, survived only until 23.8 + 1.8 days. (From Ref. 12.)
of the host, because only the first grafts were protected,
whereas the rejection process was ongoing in the second grafts.
The changes and mechanisms responsible for this protection
must be sought in the graft itself.
Removal of a longstanding graft from its original recipient and
retransplantation to a new, untreated animal seems an obvious
way to study the mechanism of allograft protection. Nirmul et al
regrafted 7-day-old skin grafts, but the transferred grafts did not
show prolonged survival as compared with non-transferred first
grafts [11]. Retransplantation experiments also have been per-
formed with long-surviving renal allografts in rats. In selected
combinations of inbred strains of this animal, it is relatively
easy to induce life-long graft survival with simple immunosup-
pressive regimens, such as a few injections of enhancing
antibodies or antilymphocyte serum. When renal allografts that
had survived for more than 6 months were retransplanted to
otherwise normal, untreated rats of the same inbred strain as
the original recipient, the onset of rejection was delayed in
comparison to that in control animals [13]. Similar results were
obtained in another study, in which retransplanted kidneys
survived 3 to 6 times longer than did fresh grafts placed in
control animals [14]. One should be careful, however, to
attribute these results to adaptation as earlier defined. In these
retransplantation experiments, changes in the afferent arm of
the response—that is, decreased immunogenicity of the graft—
cannot be distinguished from a decreased sensitivity to the
rejection mechanisms in the efferent arm. The prolonged sur-
vival thus also can be explained by the disappearance of
passenger cells from the graft during their prolonged residence
in the primary host. Loss of passenger cells does indeed seem to
be the most likely explanation for the prolonged survival.
Subsequent studies have demonstrated that the intravenous
transfer of small amounts of dendritic cells of the original donor
to the recipient at the time of retranspiantation abolishes the
difference in survival between retransplanted and primary
transplanted kidneys [15]. A study of the mechanism of adap-
tation therefore requires examination of models in which only
changes in the efferent arm of the immune response occur.
Adaptation to antibody-mediated rejection
Models that measure the resistance of fresh and long-term
grafts to the destructive effects of specific antibody have
important advantages for the study of the mechanism of gtaft
adaptation. Antibodies to major histocompatibility complex
(MHC) antigens can be administered experimentally to recipi-
ents in standardized reproducible doses; these antibodies are
cytotoxic and act only in the effector arm of the immune
response. Again, skin grafting in the mouse is an attractive
model, because the technique is simple and the destruction, or
rejection process, can be followed visually. Skin grafts in the
mouse, however, are not very susceptible to the destructive
action of cytotoxic antibodies, probably because the murine
complement system is relatively inefficient [16]. This problem
can be overcome either by administration of the antibody in
combination with an effective heterologous complement
source, such as rabbit complement, or by choosing donor skin
grafts of great antigenic disparity, such as xenografts of rat skin,
instead of allografts [171. The basic model used in our studies is
as follows: Allogeneic or xenogeneic skin is placed onto immu-
nosuppressed recipients. Immunosuppressive treatment is
aimed at maximal elimination of the immune response so that
rejection is prevented and the grafts will show prolonged,
preferably life-long, survival. An alternative and even more
attractive model used by us is the flu/flu mouse; these mice are
athymic, virtually lack T-cells, and consequently do not reject
most foreign grafts. Thus, well-established healthy grafts can be
obtained. The recipients are then challenged by the intravenous
or intraperitoneal injection of antiserum that contains antibod-
ies directed against the graft antigens. If the antigenic difference
is small, rabbit complement is given in addition. Sensitivity of
the graft to this treatment is manifested by macroscopic and
microscopic signs of necrosis, mostly within 24 to 48 hours after
the injection [18]. Figure 6 shows how the sensitivity of skin
grafts is modified by a prolonged residence on the recipient. In
this particular experiment, B10.LP flu/flu mice received skin
grafts from histoincompatible Bl0.D2 mice. The Bl0.LP nu/nu
recipients then received an injection of anti-B lO.D2 serum,
together with rabbit complement. Injections of antiserum given
during the first 3 days after transplantation were ineffective,
consistent with earlier observations showing that a period of 4
to 5 days after transplantation is required for adequate vascu-
larization of the graft [19]. After this period, there is a rapid rise
in sensitivity of the grafts, which is maximal around day 8,
Injections given later gradually become less effective. The
decreased sensitivity is not only reflected in a diminishing
percentage of partially and totally necrotic grafts, but also in the
time necessary for complete necrosis to occur after the injection
of antibodies and complement, that is, from 24 to 48 hours at
day 8, to 5 to 7 days with injections given at day 28.
To prove that the decreased sensitivity at days 14 to 50 was
indeed caused by changes in the graft and was not influenced by
decreased immune responsiveness of the host, we induced
antibody-mediated rejection in a single recipient carrying two
grafts, which were transplanted at different times. The results of
the experiment are depicted in the upper panel of Figure 7. A
14 16 18 20 22 24 26 28 30 32
Days after skin graft
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Fig. 6. Adaptation to antibody-mediated rejection. Effects of a single
injection of alloantiserum and rabbit complement on skin allografts of
increasing age in nu/nu recipients. Numbers on top of the diagram refer
to the total number of animals used in each experimental group. (From
Ref. 18.)
second B10.D2 skin graft was transplanted onto the B10.LP
flu/flu recipients 21 days after the first graft; antibody and
complement were injected 7 days later. The older grafts showed
decreased sensitivity to the antibody and complement, whereas
the new grafts were rapidly destroyed. Thus decreased efficacy
of the immunologic effector mechanisms of the recipients was
eliminated as an explanation for the protection of the older
grafts. The phenomenon meets the definition of adaptation; the
older grafts were protected against an intact immune reaction,
which was artificially induced by the administration of antibody
in this model. Adaptation therefore is a general phenomenon
occurring not only in cellular but also in antibody-mediated
immune reactions.
Mechanisms of adaptation
What accounts for this series of seemingly disparate obser-
vations? Several hypotheses seek to explain the adaptation
phenomenon. One is the assumption that during long-term
residence of the graft, the endothelium of the graft vessels is
gradually replaced by the host endothelium, and that this
process leads to the disappearance of foreign antigens. Because
the graft endothelium is considered the primary target for both
cell-mediated and antibody-mediated rejection [201, adaptation
to both processes can be expected in spite of the continued
presence of donor antigen in the tissues beyond the vascular
borderline and in spite of an intact immune-response system. A
second hypothesis is that changes in the expression of the MHC
antigens in the graft decrease the ability of the effector systems
to recognize the graft as foreign. Yet a third hypothesis is that
changes in vascularization, and thus perfusion, of the graft can
occur, and that these alterations can decrease the amount of
cellular or humoral mediators delivered to the graft. The
balance between destructive and repair mechanisms may be
altered to the advantage of the latter, and the graft can escape
from the destructive process. Let us explore these three
hypotheses.
Replacement of endothelium. Vascularization of full-thick-
ness skin grafts, which occurs via the formation of anastomoses
old
10
Rejection of fresh and
retranspianted grafts
Fresh Retransplanted
Fig. 7. Mechanism of adaptation. A second skin allograft transplanted
21 days after the first is completely sensitive to antibody and rabbit
complement, whereas the older grafts placed on the same recipient
show adaptation (upper panel). Retransplantation of 28-day-old grafts
to new recipients re-establishes the sensitivity of these grafts to that of
fresh (7-day-old) grafts (lower panel). (Modified from Ref. 18.)
between recipient and donor vessels, leads to an established
blood flow in the graft after 4 to 5 days. If donor endothelium
were subsequently replaced by that of the host, insensitivity of
the established graft to injected antibody would continue to
exist even after retranspiantation of the graft to a new host.
Figure 7 (lower panel) shows that this is not the case for murine
skin allografts, however. Grafts that had survived for 28 days
on their primary hosts regained complete sensitivity to antibody
after retransplantation. Much disagreement exists in the litera-
ture about this issue; some investigators have found evidence
for endothelial replacement in rat skin grafted to mice [211, but
we have not been able to confirm this finding. Even 170 days
after transplantation, we find persistent expression of donor
antigens on the vascular endothelium and are able to induce
antibody-mediated destruction [221. Nor has evidence been
obtained for endothelial replacement in primarily vascularized
grafts, such as kidney or heart grafts [23, 24]. Replacement of
endothelium therefore does not seem a satisfactory explanation
for graft adaptation.
Decreased MHC antigen expression. The glycoproteins that
form the structural basis of the MHC antigens can be divided
into two classes. Class-I antigens consist of two chains: a 45,000
dalton heavy chain penetrating the cell membrane is non-
covalently linked to a 12,000 dalton chain known as /3-2-
microglobulin. The genes coding for the heavy chains are
polymorphic; in humans they are located on the HL-A—A, -B,
and -C loci of the MHC on the sixth chromosome; 13-2-
microglobulin is coded for outside the MHC on the 15th
chromosome. Class-Il antigens consist of two almost equally
large chains of 34,000 and 29,000 daltons. These also are
non-covalently linked and both are anchored in the cell mem-
brane. In humans, class-I! antigens are coded for by polymor-
phic genes in the D region of the MHC. Antigenic structures
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Fig. 8. In-vivo binding of radio/abe/ed anti-
c/ass-! monoclonal antibody to mouse skin
a//ografts. The recipients were treated with
cyclosporine to prevent rejection. Injected
radioactivity was 6 x iO cpm per mouse.
Grafts were removed after 4 hours, and
radioactivity of the entire graft was counted(• •). MHC-compatible skin grafts carried
by the same recipients were used as controls
(S---•). (From Ref. 35.)
closely similar to those in humans have been detected in many
species but have been studied most extensively in the mouse; in
this species the class-I and -II antigens have been termed H-2
and Ia antigens respectively.
The tissue distribution of the two classes of MHC antigens is
quite different. Class-I antigens are present on virtually all cells,
but when the immune system is not noticeably stimulated,
differences exist in the levels of antigen expressed (reviewed in
Ref. 25). Under basal circumstances, the expression is mostly
low or even undetectable on neuronal cells, striated muscle
cells, exocrine gland cells, corneal endothelium, trophoblast,
and mature spermatozoa. Class-Il antigens are primarily ex-
pressed on the bone-marrow-derived cells that have a function
in the immune response (cells of the monocyte-macrophage
lineage, dendritic cells, Langerhans cells, B-cells, and stimu-
lated T-cells). Class-I! antigens also can be found, generally
sparsely distributed, on some other cell types. In humans,
endothelial cells express class-Il antigens, and these antigens
also are weak and patchily expressed on renal proximal tubular
cells.
The variability of MHC antigen expression was first noted in
cell cultures in vitro. Soluble mediators released by activated
T-cells stimulate the expression of MHC antigens. The soluble
mediators not only increased the concentration of MHC anti-
gens, but also could induce the expression of class-I! antigens
on non-lymphoid cells that were previously negative (reviewed
in Ref. 25). The interferons, and especially interferon-y, proved
to be the most potent stimulators of MHC antigen expression
[26]. The factors causing increased expression of MHC antigens
in vivo probably are similar to those identified in vitro. Activa-
tion of T-cells during allograft rejection and graft-versus-host
disease leads to considerable increases of MHC antigen expres-
sion. Non-allogeneic stimuli, such as contact hypersensitivity,
infection, or autoimmune disease, also can increase MHC
antigen expression at the site of inflammation. Comparable to
its strong stimulation of MHC antigen expression in vitro, the
intravenous injection of recombinant interferon-y into mice
causes a widespread induction and increase of both class-I and
class-Il antigens [27].
In the absence of stimulatory factors, cells in culture can
spontaneously lose class-I antigens [28]. In addition, several
substances can actively suppress the MHC antigen expression
in vitro and in vivo. Prostaglandins, s-fetoprotein, and cortico-
steroids inhibit class-Il antigen expression on mouse macro-
phages even in the presence of interferon-y [29—31]. In vivo,
local suppression of class-I! antigen expression was observed
when prednisolone was infused directly into rat renal allografts
[32]. The administration of cyclosporine to dogs suppresses the
expression of class-I! antigens on endothelial cells that nor-
mally are positive for these antigens [33].
We have tried to relate the adaptation seen in murine skin
grafts to changes in expression of MHC antigens. The presence
of MHC antigens in the grafts was investigated by in-vivo
injection of radiolabeled anti-class-I and anti-class-I! monoclo-
nal antibodies, which were specifically directed against the
MHC antigens of the donor strain [34, 351. Four hours after the
injection, the grafts were excised and the amount of radioactiv-
ity of the entire graft was determined by y-counting. By using
autoradiography, and in additional studies with fluorescent
antibodies, we could demonstrate that the antibody had become
bound to the capillary endothelium of the graft. Figure 8 shows
the changes in the binding capacity of skin allografts for a
monoclonal antibody against class-I antigen on different days
after transplantation. Cellular rejection of these grafts was
prevented by daily administration of cyclosporine to the recip-
ients. We observed maximal binding (that is, maximal expres-
sion of MHC antigens) at days 5 and 8 after transplantation;
binding ability thus correlated with the period of maximal
vulnerability to antibody-mediated destruction. After day 10,
binding of antibody gradually decreased to a background level,
which was reached at day 18. Skin grafts that were MHC-
compatible with the recipient strain and that were carried by the
same recipients show a background uptake of radiolabeled
antibody throughout the experiment. We observed comparable
5
Day after transplantation
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Fig. 9. Influence of immunosuppressive treaimeni on the in-vivo bind-
ing of radiolabeled anti-class-I monoclonal antibody to mouse skin
allografts. The recipients were treated daily with cyclosporine, for 3
weeks. Treatment was discontinued on day 21 after transplantation in
one group ( •), whereas the control group (•---•) received
cyclosporine throughout. (From Ref. 35.)
changes when we used specific antibodies against class-Il
antigens [34].
The occurrence of a gradual decrease of MHC antigen
expression after transplantation would elegantly explain the
adaptation of longstanding murine skin grafts. Decreased
expression is maintained provided that the immune response of
the host remains suppressed. This adaptation is illustrated by
the experiment depicted in Figure 9. When cyclosporine treat-
ment was withdrawn at day 21 after transplantation, we de-
tected enhanced class-I antibody binding as compared with that
in a control group receiving cyclosporine throughout the exper-
iment. Again, comparable observations were made with anti-
class-Il antibodies [34]. A low expression of MHC antigens in
longstanding grafts probably represents a quiescent state typi-
cal of normal, healthy tissue and is a state regained by a graft
after a period of increased expression induced by the transplan-
tation procedure and the accompanying inflammatory pro-
cesses. Milton and coworkers demonstrated that not only
antigenic stimuli but also the trauma of the transplantation
operation itself causes an increased expression of MHC anti-
gens [36]. Isografts of hearts and kidneys in rats showed a
transiently increased expression of class-I antigens immediately
after transplantation, even though the hosts could not mount an
allogeneic immune response against such grafts. The fact that
longstanding skin grafts again become sensitive to antibody-
mediated rejection after retransplantation onto new hosts also
could be explained by an increase in antigen expression.
What is the evidence that an increased expression of MHC
antigens makes a graft more sensitive to rejection? In-vitro
studies have established that the extent of lysis of target cells
induced by MHC antibodies correlates with the concentration
of the target antigen on the cell membrane [37]. No direct
evidence indicates that this correlation also holds for the
destruction by cytotoxic T-cells. But arguments that cytotoxic
T-cell activity correlates with the amount of antigen on the cell
membrane can be derived from the observation that increased
expression of class-I antigens on tumor cells makes these cells
more sensitive to MHC-restricted cell-mediated lysis [38]. A
relationship between antigen concentration and damaging po-
tential of the corresponding MHC antibodies also has been
demonstrated in vivo in animal studies in which transplanted
allogeneic tumors were used as target tissues [39].
The experimental data are fairly solid, but it is difficult to
obtain direct proof that the variability of MHC antigen expres-
sion plays a role in long-term graft acceptance in clinical renal
transplantation. Several studies demonstrate that class-I and
class-Il antigen expression increase in the kidney during rejec-
tion episodes [40, 41]. The increase in class-Il expression on
renal tubular cells even can be used as a diagnostic sign of
rejection [41]. It remains difficult, however, to determine
whether this increase in class-Il expression plays an active role
in the rejection process or whether this rise is merely a
consequence of rejection. Some observations suggest that the
increased expression is not simply a bystander phenomenon.
Treatment of renal transplant patients with recombinant a-
interferon to prevent viral infection has led to severe rejection
episodes [42]. As I mentioned before, interferons are the
strongest inducers of MHC antigens. Viral infections lead to an
increase of systemic interferon levels [43] and often are asso-
ciated with renal graft rejection [44, 45]. An increase in MHC
antigen expression might be the triggering mechanism in these
rejections. It is possible that the immunosuppressive effects of
cyclosporine and corticosteroids are at least partly related to
their suppressive effects on the expression of MHC antigens;
the studies I mentioned earlier bolster this possibility [31—35]. A
low level of MHC antigen expression also might explain why
liver grafts are less susceptible to rejection than are grafts of
other organs [46].
Decreased vascularization. The classic histologic studies by
Medawar of skin grafts in rabbits showed that a rich vascular
network is formed during ingrowth of the grafts [47]. The
vessels decrease in size after day 8 and are comparable to
normal skin vessels around day 24. In mice, similar changes in
the vascularization of skin autografts have been described [48,
49]. It is conceivable that the degree of vascularization greatly
determines the accessibility of the graft antigens to antibody or
to cytotoxic lymphocytes. The disappearance of hypervascula-
rization in skin grafts coincides with the decrease of sensitivity
to antibody-mediated rejection and thus might be responsible
for the adaptation of skin grafts. In this concept, adaptation is
not an actual decrease in sensitivity of the grafted tissue itself.
Rather, adaptation merely reflects the recovery of the graft
from the trauma of the transplantation procedure, which caused
a transient state of hypervascularization. A decreased degree of
vascularization as a cause of adaptation perfectly fits with the
observations in the clinical case that we are discussing today.
The role of hemodynamic factors in immunologically
mediated diseases
Although the main topic of this forum is adaptation of an
allograft to immunologic attack by the host, the protection of
— —I,,
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part of the graft in the patient we are discussing leads us to
examine other clinical situations in which an immune disease is
influenced by circulatory effects. In this regard the patient
under discussion shows many similarities to the rare patient
with unilateral glomerulonephritis; only 9 such patients were
reported between 1944 and 1985. In all 9, blood flow to the
kidney that was protected from the injury was decreased. Two
of the 9 had a hypoplastic kidney as a consequence of long-
standing hydronephrosis [50, 51]; all the others had a renal
artery stenosis [52—55]. The causes of the glomerulonephritis
were variable. The first description of unilateral glomerulone-
phritis by Fahr in 1944 concerned a patient with diffuse extra-
capillary glomerulonephritis and a rapidly progressive clinical
course [50]. A second patient with this disease was reported 30
years later [51]. Four of the 9 patients had proliferative glomer-
ulonephritis [51—54], and 2 had glomerulonephritis secondary to
systemic disease; one of these had lupus nephritis [54] and the
other patient was a child with Schönlein-Henoch purpura [51].
The ninth patient is especially interesting, because it is the only
case in which immunofluorescence and electron-microscopic
studies of both the ischemic and the nonischemic kidney were
performed [55]. Nephrotic syndrome developed during treat-
ment with captopril for severe hypertension. Arteriography
revealed that the right renal artery, which had been patent
before treatment with captopril, had become occluded and
appeared to be perfused only by collateral vessels. The left
kidney (which had a patent artery) showed typical signs of
membranous glomerulonephritis. Immunofluorescent studies
revealed extensive granular deposits of IgG, IgM, and C3 in the
glomerular capillary wall. Electron microscopy disclosed large,
electron-dense deposits on the subepithelial side of the giomer-
ular basement membrane, findings characteristic of membra-
nous glomerulonephritis. In the right (ischemic) kidney, the
glomeruli manifested only ischemic changes, and immunofluo-
rescent examination was negative. Some sparsely distributed,
very small deposits were visible at the epithelial side of the
glomerular basement membrane on electron microscopy. This
latter finding suggests not that the deposition of immunoglob-
ulins was prevented by decreased perfusion, but rather that
their further aggregation to larger immune complexes was
inhibited.
The influence of local perfusion on the induction of immuno-
logic damage also is apparent from the observations that, in
biopsies of patients with acute glomerulonephritis, ischemic
glomeruli are not affected [56, 57]. This observation raises the
question of whether intrarenal differences in perfusion also are
responsible for the focal and segmental character of some
immunologically mediated forms of glomerulonephritis, such as
systemic lupus erythematosus or Schölein-Henoch purpura.
In experimental studies, only a few investigators have fo-
cused on local factors that might determine the localization of
vascular lesions. Artificially induced hypertension aggravated
the glomerular, cardiac, and vascular lesions in rabbits with
acute serum sickness [58]. In a similar model, the inflammatory
lesions in large arteries were most prominent at areas of high
turbulence [59], The induction of clip hypertension in rats with
nephrotoxic serum nephritis also increased glomerular prolifer-
ation and sclerosis in the non-clipped kidney [60]. On the other
hand, Germuth and colleagues more than 20 years ago showed
that the acute, proliferative, and exudative lesions in rabbits
with acute serum sickness were reduced, or even completely
prevented, if the renal artery was narrowed by 50% or if the
ureter was ligated. Moreover, immunofluorescent examination
revealed no deposition of IgG in the unaffected glomeruli,
whereas extensive histologic lesions and immune deposits were
apparent in the contralateral kidney [61]. These results suggest
that hemodynamic factors play an important role in inducing
immune-mediated damage. A more recent study tried to char-
acterize these factors more specifically [62]. Hebert et al
measured the uptake of infused radiolabeled immune com-
plexes in kidneys of normal dogs in which the blood flow to one
kidney was decreased by renal artery constriction or by eleva-
tion of the ureteral pressure. They found a linear relationship
between immune-complex uptake and the reduction in renal
blood flow. They reasoned that capillary hydrostatic pressure
itself could not be the most important factor in the trapping of
immune complexes, because both causes of decreased renal
blood flow (that is, renal artery stenosis and elevation of
ureteral pressure) gave similar results, although they have
opposite effects on capillary hydrostatic pressure. It remains
doubtful whether these findings are fully representative of the
events occurring during glomerulonephritis, because the vast
majority of the infused immune complexes appeared to be
trapped at nonglomerular sites in Hebert's experiments. The
significance of these findings also is questionable in light of the
new findings on the causes of glomerulonephritis [63]. It ap-
pears that the binding of antibodies in the giomerulus to fixed or
planted antigens plays a much more important role than does
deposition of circulating immune complexes. Thus, although it
is obvious that decreases in perfusion can protect the kidney
against immunologic damage, the exact mechanism of this
protection remains unclear.
Renal artery stenosis also can protect a kidney against
damage that is presumably nonimmunologic. The classic exam-
pies are protection against the direct damaging effects of high
blood pressure in patients with hypertension and unilateral
renal artery stenosis, and protection of animals with experimen-
tal Goldblatt hypertension [64]. It is difficult to understand how
unilateral renal artery stenosis can protect a kidney against
diabetic nodular glomerulosclerosis, however [65]. This unique
observation conforms with the earlier notion that the nodular
lesions of diabetic nephropathy do not develop in ischemic
glomeruli [56]. Indeed, these observations support the recent
view that glomerular hyperfiltration, probably in combination
with raised blood pressure, is an important determinant of
diabetic nephropathy [66].
Summary
The experimental and clinical data suggest that both a de-
crease of antigen expression and decreased perfusion can
protect against immunologically mediated destructive pro-
cesses. In the adaptation of skin grafts, these factors could be
interrelated. Inadequate perfusion might lead to a decreased
delivery of substances that stimulate MHC antigen expression.
This course of events also could explain the protection in the
patient presented here. Immune deposits were completely
absent in the protected segment of the kidney, although immune
deposits were abundantly present in the remaining part of the
kidney, and circulating anti-donor antibodies were demonstra-
ble after the transplanted kidney had been removed. The limited
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availability of frozen biopsy material has prevented us from
comparing the expression of MHC antigens in both kidney
segments using monoclonal antibodies. But such studies might
be done in experimental kidney transplants with an artificially
induced stenosis of the renal artery.
Except when an arterial stenosis is present, we have little
reason to assume that perfusion gradually decreases in long-
standing kidney grafts as it does in skin grafts. Therefore, if
adaptation plays a role in the gradual decrease of the sensitivity
to rejection in longstanding kidney grafts, this phenomenon
must be attributed to a decreased expression of target antigens
as a consequence of factors other than decreased perfusion.
The most likely candidates are the immunosuppressive drugs,
such as cyclosporine and prednisone, which decrease MHC
antigen expression.
Let me conclude by returning to my main theme of graft
adaptation. It seems appropriate to end this review with a
quotation from one of Woodruff's original publications on this
subject: "If the phenomenon [adaptation] applies to homotrans-
plants of normal tissues to sites other than the eye, I think it
almost certain that the clinical homograft problem will be
solved; if it does not, the problem may prove insoluble" [9].
Although our insight into the rejection process has increased
considerably, we still do not know which factors are most
important in determining the long-term survival of primarily
vascularized grafts.
Questions and answers
Da. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Could you com-
ment on the possible interplay between host and graft factors
involved in acceptance of the graft? For instance, is there any
link between down-regulation of the expression of MHC anti-
gens and deletion of antigen-specific cells?
PROF. KOENE: This is a very complicated problem. I would
like to mention one interesting observation that stems from the
study in which prednisolone was infused locally into rat kidney
grafts [32]. These grafts showed a decrease in class-IT antigen
expression and had a prolonged survival, whereas the number
of lymphocytic infiltrates present in these kidneys was the same
as those in untreated control grafts. So the presumed effector
lymphocytes were there, but apparently they were not stimu-
lated to set off the chain of events that leads to rejection. This
observation shows that down-regulation of MHC antigen
expression does not necessarily lead to elimination of antigen-
reactive effector cells. These observations also explain why we
often find lymphocytic infiltrates in the renal biopsies of pa-
tients treated with cyclosporine, or with azathioprine and
prednisone, while there are no clinical signs of rejection. I think
that it is more important to look for large, activated lympho-
cytes. These are not easy to identify in core biopsies, but they
can be seen in fine-needle aspirates during acute rejection
episodes, as shown by Bishop and coworkers [67].
DR. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York): What is
the relationship between "adaptation" and graft "tolerance?"
PROF. KOENE: In my opinion these should be considered two
essentially different phenomena. As I briefly mentioned before,
the term adaptation has been used by some authors in a broader
sense to include a decreased immunogenicity of the graft by the
disappearance of passenger cells from the graft. In the definition
that I have adopted, which originally was proposed by Wood-
ruff [91, adaptation is the protection of a graft from an already
established immune response. In a similarly confusing way, the
term tolerance has been used to describe completely different
mechanisms of graft acceptance. It is often used as a broad
term, meaning that the graft is tolerated by the host by any
possible protective mechanism; but in the strict sense, toler-
ance refers to removal or inactivation of specific antigen-
reactive cells from the host. If both terms are used in their strict
sense, the most important difference between adaptation and
tolerance is that in adaptation the immune response against the
graft is still active, whereas in tolerance this response is absent
or completely suppressed.
PROF. PEKKA HAYRY (Professor of Transplantation Surgery
and Immunology, University of Helsinki, Helsinki, Finland): I
believe that in your "adaptation" mechanism, several systems
are operating together. For example, if inflammation is induced
in a part of the graft, it might protect another part of the graft in
the same way as a large liver graft can protect a kidney or a
heart graft. This might be one explanation for only part of the
kidney being rejected in the patient under discussion. Second, I
am not sure whether endothelium is replaced in many of the
grafts. In primarily vascularized grafts, it is not. In skin it must
be, and in pancreatic islets, donor capillary endothelium is
replaced by recipient endothelium. Would you please comment
on these possibilities?
PROF. KOENE: Your first remark relates to the fact that a
large graft might keep the effector systems so busy that another
grafted tissue might escape from rejection. Indeed, one can
imagine that in cell-mediated rejection, there might not be
enough cells available to do the work somewhere else. Exper-
imental evidence shows that this can occur, but it is more
difficult to conceive that the same will happen when circulating
antibody is present. The patient I described had a chronic
vascular rejection most likely mediated by circulating antibod-
ies, as can be deduced from the histology of the graft and from
the demonstration of cytotoxic antibodies in the serum. I find it
difficult to understand why the antibody does not deposit in the
graft when one can see contrast medium reaching the postste-
notic part of the kidney and when antibody is present in
measurable titers in the circulation. Repair mechanisms could
be obscuring destructive changes, but these still would not
explain why immunofluorescence was negative in this part of
the graft.
Your second question implies that you believe that skin grafts
show replacement of endothelium. I do not think that endothe-
hal replacement takes place in the skin. We have been able to
show persistent expression of donor antigens on the vascular
endothehium of rat skin xenografts even after 170 days of
residence [221. Pancreatic islet grafts are different in this regard,
because such grafts represent a nonvascularized tissue that will
be invaded by host vessels after transplantation; this occur-
rence is similar to the invasion of a transplanted tumor by host
vessels.
PROF. HAYRY: Are you certain that chronic vascular rejec-
tion is mediated by antibody and not by cells?
PROF. KOENE: There is convincing experimental and clinical
evidence that antibodies, if administered or if present in the
host, can damage the graft.
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PROF. HAYRY: But that is only the case in hyperacute
rejection. There are very few papers on the role of antibody in
chronic rejection.
PROF. KOENE: True, but if chronic vascular rejection had an
important cellular component, one would expect to find a
histologic correlate thereof. We do not see lymphoid effector
cells in the vessels, however. We only see destruction of
endothelial cells, platelet aggregation, intravascular coagula-
tion, and intimal fibrosis.
PROF. LEENDERT A. VAN Es (Chief, Department of Nephrol-
ogy, University of Leiden, Leiden, The Netherlands): My
question pertains to delivery versus concentration of mediators.
We can reasonably assume that decreased flow will lead to
decreased delivery of immunocompetent cells or antibodies
when these are present in limited amounts. This is more difficult
to understand if an excess of antibody is present. If the
concentration rather than flow of lymphokines or other media-
tors is important, I would expect that a renal artery stenosis
would play less of a role. Can you explain the protection of the
lower part of the graft fully by hemodynamic factors?
DR. KOENE: In the situation that we are talking about, there
is probably continuous stimulation of the immune response, and
the antibody is chronically delivered. I fully agree with you that
it is difficult to understand why antibody is not bound, even in
a poorly perfused graft, if it is continuously present in the
circulation. Therefore I am inclined to believe that the disap-
pearance of MHC antigens from the vascular endothelium
protected the poorly perfused segment.
PROF. YVES PIRsON (Renal Physician, Department of
Nephrology, Cliniques Universitaires St. Luc, Brussels, Bel-
gium): In a series of animal experiments, Monaco demonstrated
increased tolerance of kidney grafts by infusing donor bone
marrow a few days after renal transplantation [681. He was able
to show the establishment of donor cells (possibly suppressor
cells) in some grafts. Do you think that such a procedure could
be applied in clinical transplantation?
PROF. KOENE: The experiments you are referring to were
performed in mice that received allogeneic skin grafts followed
by an injection of donor bone marrow 6 days later [681. This
model is complex, because the recipient mice also were treated
with antilymphocyte serum. The donor cells responsible for the
graft prolongation have not been precisely identified, but evi-
dence suggests that they possess suppressive activity in mixed
lymphocyte reactions in vitro. Ildstad and Sachs made another
fascinating observation at the U.S. National Institutes of
Health. They found that the reconstitution of bone marrow in
irradiated mice with a mixture containing both T-cell-depleted
syngeneic and allogeneic or xenogeneic bone marrow cells
leads to specific acceptance of skin allografts or xenografts [691.
It will be necessary to show that these manipulations are also
effective in larger animals, but if so, this certainly seems an
attractive approach for obtaining specific graft tolerance in
clinical transplantation.
PROF. FRITZ BUHLER (Head, Hypertension Unit, University
Hospital, Basel, Switzerland): Cyclosporine suppresses class-I
and class-Il antigen expression, and it is strongly immunosup-
pressive. Why are aspirin and other nonsteroidal antiinflamma-
tory drugs, which interfere with prostaglandin synthesis, not
immunosuppressive?
PROF. KOENE: The prostaglandin antagonists would be ex-
pected to decrease, and not increase, graft survival, because
prostaglandins suppress MHC antigen expression. Theoreti-
cally, the inhibitors would cause an increase of MHC antigen
expression and make the graft more sensitive to rejection. Most
studies have confirmed that these agents heighten the immune
response in vitro and in vivo [70]. With regard to graft rejection,
the results are controversial. Some workers have found pro-
longed skin-graft survival in the mouse when indomethacin was
given along with low doses of corticosteroids [71]. Others,
however, have found decreased survival when indomethacin
was used alone [72].
PROF. BUHLER: But is the adaptation process the key event in
long-term graft acceptance?
PROF. K0ENE: I do not believe that there is one single key
mechanism. What we observe is that the sensitivity of a graft to
the rejection process decreases with time. The longer the graft
is there, the less sensitive it will be. As I showed you, different
factors can play a role in long-term graft acceptance. In the
complex clinical situation, it is very difficult to determine the
precise role of each factor. The important thing I want to point
out is that adaptation is very likely to be one of these factors. It
is a mechanism that has not received much attention in the past.
The study of its role might teach us how we can control
rejection even better than we do now. We do quite a good job
by reaching one-year survival rates between 80% and 90% in
renal allografts, but still these results are obtained at the
expense of potentially dangerous immunosuppressive therapy.
PROF. JAN J. WEENING (Chief, Division of linmunopathol-
ogy, University of Groningen, Groningen, The Netherlands):
What were the effects of IL-2 treatment late, and of anti-class-Il
antibodies early, in the murine transplantation model?
PROF. KOENE: You raise two different problems. We have
not tried IL-2 treatment in our mouse model, but we have tried
to increase MHC antigen expression and to induce antibody-
mediated rejection in longstanding grafts by treatment with
y-interferon. So far we have not been successful. We are,
however, not certain that enough of the systemically adminis-
tered interferon was delivered to the graft. We have not
measured that. We currently are trying to increase MHC
expression by the administration of mixed lymphocyte culture
(MLC) supernatants and also by the transfer of sensitized
lymphocytes, but results of these experiments are not yet
available.
Your second question relates to the effects of administration
of anti-class-lI antibody early after transplantation. Antibodies
given at transplantation or within the first days thereafter can
have two opposite effects: they can be destructive if they bind
to the graft and activate secondary mediators, such as the
complement system. However, if they cannot destroy the graft
by themselves (as is the case for alloantibodies in the mouse
because they activate complement very poorly), they paradox-
ically can block the immune response. That is an example of
so-called passive immunologic enhancement. It is probably a
central blockade of the immune response in which the antibody,
together with antigen released from the graft, becomes bound as
an immune complex to the antigen-reactive cells. These cells
are then opsonized and the immune response is delayed or even
completely suppressed [73].
PROF. HAYRY: What about noncompliant patients? Do the
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patients who stop taking immunosuppressive drugs reject their
grafts?
PROF. KOENE: We all know patients whom we suspected of
not taking their drugs and who rejected their grafts. Also,
patients with chronic hepatitis who could not be given high
enough doses of azathioprine have rejected their grafts even 5
or 6 years after transplantation. On the other hand, there are
isolated reports of patients who tolerated their graft even
though they stopped taking immunosuppressive drugs some
years after transplantation. Certainly some patients can do
without any immunosuppression once their grafts have become
established, but these individuals seem to be the exception to
the rule, and we have no means of identifying them. The only
way to do this is by discontinuing treatment and waiting for a
rejection to occur. Obviously, this is not an advisable approach.
DR. HARRINGTON: I believe I can answer in part Dr. Häyry's
question on noncompliance in transplant patients. Several years
ago we collected some interesting data on what happens to
transplant patients who stop taking their immunosuppressive
medications [74]. We identified 48 patients in the U.S. who had
stopped therapy on their own from a total transplant population
of over 6000. Of the 48 patients, 21 experienced graft failure
before the noncompliance was discovered, and only 6 did well
for a prolonged period. Our data demonstrated that at no point
after transplantation is it safe to discontinue immunosuppres-
sive therapy. The data also demonstrate that noncompliance in
transplant patients is exceedingly unusual.
DR. EMILE DE HEER (Department of Pathology, University
of Leiden, Leiden, The Netherlands): You probably are familiar
with the kidney transplantation model described by Hutchinson
and Morris, in which they induce graft acceptance by donor-
specific blood transfusions [75]. Cultured infiltrating T-cells
from tolerant rats turned out to be graft-specific cytotoxic
T-cells that had failed to exert their cytotoxic function in vivo.
Do you think that this failure in their model is caused by
decreased expression of target epitopes in the graft as a
consequence of adaptation?
PROF. KOENE: That seems an attractive explanation. The
graft prolongation in the model you mention is most probably
caused by T-suppressor cells [75]. It is conceivable that sup-
pression of the immune response by these cells prevents the
production of lymphokines and thereby MHC antigen expres-
sion, so that targets for the cytotoxic cells on the endothelium
of the graft are absent. One should not forget, however, that
many different immunosuppressive mechanisms play a role in
clinical transplantation. Goulmy et al showed that patients with
longstanding and well-functioning grafts can lose cell-mediated
lympholysis reactivity against their donors [1]. This loss might
be due to the appearance of suppressor cells or to the disap-
pearance of antigen-reactive cells. The non-reactivity was spe-
cific for the HL-A antigens of the donor. Alternatively, anti-
idiotypic antibodies can develop that cause specific blockade
[2]. Graft adaptation may be another factor that protects
longstanding grafts against rejection. It seems likely that none
of these protective mechanisms will by itself guarantee long-
term graft survival, but rather that a combination of mecha-
nisms and their interplay ultimately are responsible for protec-
tion of the graft.
DR. DE HEER: Was the failure of the effector cells in exerting
their function in the in-vitro experiments that you mentioned
due to the disappearance of MHC antigens from the target
cells?
PROF. KOENE: Not in the studies by Goulmy et al. This group
used donor lymphoid cells that were collected at the time of
grafting.
PROF. PIERRE VERROUST (Director of Re.search, INSERM,
Hôpital Tenon, Paris, France): What is the mechanism of
protection of thyroid grafts in the eye in the experiments by
Woodruff?
PROF. KOENE: Woodruff hypothesized that the anterior
chamber of the eye is an immunologically privileged site and
that this exemption is related to the absence of vascularization
[8]. One explanation is that the graft becomes vascularized so
slowly that it already has undergone adaptive changes and has
become resistant to the rejection mechanisms. It seems more
likely, however, that the location in the anterior chamber
decreases the immunogenicity of the graft because the passen-
ger cells that have to present the antigen cannot leave the
anterior chamber and thus cannot reach the lymph nodes. After
vascularization has become established, these cells already
have disappeared by cell death; this is similar to what happens
when thyroid tissue is cultured during a few days in vitro. The
lymphoid cells in the tissue do not survive this procedure.
Subsequent grafting of the cultured thyroid does not lead to a
rejection response [4, 51. This finding also explains why a
concomitantly placed subcutaneous graft, which contains many
passenger cells and is strongly immunogenic, will destroy the
graft in the eye.
PROF. HAYRY: I wish to offer a word of warning about the
different tolerance models. These models might look the same
superficially, but they are different. The extent of inflammation
in the kidney is vastly different. In cyclosporine A-induced
tolerance in the rat, there is very little inflammation. In anti-
thymocyte-globulin-induced tolerance, there is much inflamma-
tion, and this is also the case in "tolerance" induced by
donor-specific transfusions (DST) in the rat. Do you agree?
PROF. KOENE: I completely agree that the mechanisms of
so-called tolerance in different models vary widely. But I do not
agree with your explanation of the mechanism of the beneficial
effect of DST. It is not at all certain that the DST by itself leads
to specific immunosuppression. It is important to realize that in
clinical transplantation, recipients of living-donor kidneys
treated with donor-specific transfusions before transplantation
can develop severe rejection episodes very early after trans-
plantation. Fortunately, these rejections respond very well to
anti-rejection treatment, and thereafter the graft generally is
tolerated without further problems. This somewhat paradoxical
course in these patients has led to the speculation that DST
actually might immunize the recipient to the donor antigens
[761. The ultimately favorable course would be explained by the
fact that in the severe rejection that occurs early after trans-
plantation, the majority of cells reactive to the donor antigens
will participate. These cells are then effectively eliminated by
the rejection treatment, so that ultimately a state of tolerance
develops, that is, the absence of donor-specific antigen-reactive
cells. Whether this explanation of the beneficial effect of DST is
correct remains to be seen, but it can be concluded that the
inflammatory changes seen initially in the graft after DST could
reflect rejection activity and not tolerance.
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